Troubled Immunocore Reawakens With New $130m Funding

Company Diversifies Into Hepatitis B

After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?

OXFORD, ENGLAND - JANUARY 25: A view on the streets in Oxford, England on 25 January, 2018
The Oxford, UK-headquartered company needs to generate proof of concept data for its T-cell receptor immunotherapy

Five years ago, Immunocore Ltd. broke a European biotech fundraising record when it raised a hefty $320m in its debut funding round, and looked set to be a real contender among emerging immunotherapy companies.

Fast forward to 2020, and the Oxford, UK-headquartered firm has precious little to show from that series A capital, having...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip